文献速递肝病

受控衰减参数(CAP)技术评估脂肪变的个体患者数据荟萃分析

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
PubMed 文献 · J Hepatol · 2016-12-28

该个体患者数据荟萃分析纳入19篇文献中2735例经组织学验证的CAP数据,评估CAP对脂肪变分级(S0-S3)的诊断准确性并确定最佳截断值。结果显示,NAFLD/NASH、糖尿病和BMI等因素会影响CAP值,区分S0以上和S1以上的最佳截断值分别为248 dB/m和268 dB/m。作者指出,解读CAP时需考虑患病率、病因、糖尿病和BMI,尚需纵向数据证明CAP与临床结局的关系。

要点

  • CAP值受NAFLD/NASH、糖尿病和BMI影响,解读时需考虑这些协变量。
  • 区分S0以上的CAP最佳截断值为248 dB/m(95%CI 237-261)。
  • 区分S1以上的CAP最佳截断值为268 dB/m(95%CI 257-284)。

核心结论

  • CAP提供了标准化的无创肝脂肪变测量方法。
  • 解读CAP时需考虑患病率、病因、糖尿病和BMI。
  • 尚需纵向数据证明CAP与临床结局的关系。

研究设计与样本

  • 个体患者数据荟萃分析,检索文献中包含组织学验证的CAP数据(M探头,FibroScan®振动控制瞬时弹性成像)用于脂肪变分级(S0-S3)的研究。
  • 共获取19/21篇符合条件论文的数据,涵盖3830/3968(97%)例患者;考虑数据重叠和排除标准后,最终分析纳入2735例患者(37%乙型肝炎,36%丙型肝炎,20%NAFLD/NASH,7%其他)。

主要发现

  • 脂肪变分布为S0/S1/S2/S3分别为51%/27%/16%/6%。
  • CAP值(dB/m,95%CI)受协变量影响:NAFLD/NASH患者估计偏移10(4.5-17),糖尿病患者偏移10(3.5-16),每BMI单位偏移4.4(3.8-5.0)。
  • 曲线下面积分别为0.823(0.809-0.837)和0.865(0.850-0.880)。

关键数值与推荐

  • 区分S0以上的最佳截断值为248(237-261)dB/m。
  • 区分S1以上的最佳截断值为268(257-284)dB/m。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The prevalence of fatty liver underscores the need for non-invasive characterization of steatosis, such as the ultrasound based controlled attenuation parameter (CAP). Despite good diagnostic accuracy, clinical use of CAP is limited due to uncertainty regarding optimal cut-offs and the influence of covariates. We therefore conducted an individual patient data meta-analysis. METHODS: A review of the literature identified studies containing histology verified CAP data (M probe, vibration controlled transient elastography with FibroScan®) for grading of steatosis (S0-S3). Receiver operating characteristic analysis after correcting for center effects was used as well as mixed models to test the impact of covariates on CAP. The primary outcome was establishing CAP cut-offs for distinguishing steatosis grades. RESULTS: Data from 19/21 eligible papers were provided, comprising 3830/3968 (97%) of patients. Considering data overlap and exclusion criteria, 2735 patients were included in the final analysis (37% hepatitis B, 36% hepatitis C, 20% NAFLD/NASH, 7% other). Steatosis distribution was 51%/27%/16%/6% for S0/S1/S2/S3. CAP values in dB/m (95% CI) were influenced by several covariates with an estimated shift of 10 (4.5-17) for NAFLD/NASH patients, 10 (3.5-16) for diabetics and 4.4 (3.8-5.0) per BMI unit. Areas under the curves were 0.823 (0.809-0.837) and 0.865 (0.850-0.880) respectively. Optimal cut-offs were 248 (237-261) and 268 (257-284) for those above S0 and S1 respectively. CONCLUSIONS: CAP provides a standardized non-invasive measure of hepatic steatosis. Prevalence, etiology, diabetes, and BMI deserve consideration when interpreting CAP. Longitudinal data are needed to demonstrate how CAP relates to clinical outcomes. LAY SUMMARY: There is an increase in fatty liver for patients with chronic liver disease, linked to the epidemic of the obesity. Invasive liver biopsies are considered the best means of diagnosing fatty liver. The ultrasound based controlled attenuation parameter (CAP) can be used instead, but factors such as the underlying disease, BMI and diabetes must be taken into account. Registration: Prospero CRD42015027238.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2016. PMID: 28039099. doi:10.1016/j.jhep.2016.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。